| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1153-8443 | Other Identifier | World Health Organization | |
| 2008-004975-22 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel, multiple-dose schedule.
The drug being tested in this study is called TAK-438. TAK-438 is being tested to find a safe and well-tolerated dose. This study looked at pharmacokinetic (effect of the body on the drug) and pharmacodynamic properties (effect of the drug on the body) as well as look at lab results and side effects in people who took TAK-438. This study was designed as a randomized, sequential-panel, multiple repeat dose study.
The study population consisted of 4 Cohorts with 12 participants in each Cohort; with 9 participants randomized to receive a single dose of TAK-438, and 3 participants to receive placebo. Participants in each Cohort received a single dose of study drug once daily after a 10-hour fast. The starting dose was 10 mg followed by administrations of 20, 40, and 30 mg.
This single-centre trial was conducted in the United Kingdom. The overall time to participate in this study was up to 37 days. Participants made 2 visits to the clinic for screening, one 11-day period of confinement to the clinic, and 2 further visits after the confinement period. All participants were contacted by telephone 7 days after last dose of study drug for a follow-up assessment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: TAK-438 10 mg | Experimental | TAK-438 10 mg tablets, orally, once, daily, for 7 days. |
|
| Cohort 2: TAK-438 20 mg | Experimental | TAK-438 20 mg tablets, orally, once, daily, for 7 days. |
|
| Cohort 3: TAK-438 40 mg | Experimental | TAK-438 40 mg tablets, orally, once, daily, for 7 days. |
|
| Cohort 4: TAK-438 30 mg | Experimental | TAK-438 30 mg tablets, orally, once, daily, for 7 days. |
|
| Cohorts 1-4: Placebo | Placebo Comparator | TAK-438 placebo-matching tablets, orally, once, daily, for 7 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TAK-438 | Drug | TAK-438 tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | (AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC[0-tlqc]). | Days 1 and 7 |
| AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. | Days 1 and 7 |
| AUC(0-tau): Area Under the Plasma Concentration-time Curve from Time 0 to Time tau Over the Dosing Interval for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | AUC(0-tau) is a measure of the area under the plasma concentration-time curve from time 0 to time tau over a dosing interval, where tau is the length of the dosing interval. | Days 1 and 7 |
| Cmax: Maximum Observed Plasma Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. | Days 1 and 7 |
| Cmin,ss: Minimum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Day 7 | |
| Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Time the pH is Greater than pH 4 and pH 5 over a 24 Hour Period | Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7. | Over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director Clinical Science | Takeda | Study Director |
| Steve Warrington | Hammersmith Medicines Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hammersmith Medicines Research | London | NW10 7EW | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25707624 | Derived | Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015 Apr;41(7):636-48. doi: 10.1111/apt.13121. Epub 2015 Feb 23. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005764 | Gastroesophageal Reflux |
| ID | Term |
|---|---|
| D015154 | Esophageal Motility Disorders |
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C552956 | 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| TAK-438 Placebo | Drug | TAK-438 placebo-matching tablets |
|
| Day 7 |
| (Cmax-Cmin)/Cavg: Fluctuation of Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | (Cmax-Cmin)/Cavg, where Cmin is the minimum observed plasma concentration and Cavg is the average plasma concentration at steady state. | Day 7 |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax. | Days 1 and 7 |
| Terminal Elimination Rate Constant (λz) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body. | Days 1 and 7 |
| Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. | Days 1 and 7 |
| Apparent Clearance (CL/F) Pharmacokinetic Parameter for TAK-438 | CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr. | Days 1 and 7 |
| Apparent Volume of Distribution (Vz/F) for TAK-438 | Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz. | Days 1 and 7 |
| Ae(0-t): Total Amount of Drug Excreted in Urine from Time 0 to Time T for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Ae(0-t) is the total amount of drug excreted in urine from time 0 to t, where t is 24 hours on Day 1 and 48 hours on Day 7. | Day 1 and Day 7 |
| Ae(0-tau): Total Amount of Drug Excreted in Urine from Time 0 to Time tau for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | Ae(0-tau) is the total amount of drug excreted in urine from time 0 to tau, where tau equals 24 hours. | Day 1 and Day 7 |
| Renal Clearance (CLr) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul | CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose. | Day 1 and Day 7 |
| Fraction of TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Excreted in Urine (Fe) | Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100. | Day 1 and Day 7 |
| Physical Examination Findings | A baseline physical examination (defined as the pretreatment assessment immediately prior to the start of study drug) will consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) genitourinary system; and (12) other. All subsequent physical examinations should assess clinically significant changes from the baseline examination. | Baseline up to Day 9 |
| Number of Participants With Potentially Clinically Significant Vital Sign Findings | Participants with at least one potentially clinically significant post-baseline vital sign finding. Vital signs will include body temperature (oral temperature), sitting blood pressure (after sitting for 5 minutes), and pulse (bpm). | Baseline up to Day 9 |
| Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings | Full 12-lead ECGs will be recorded using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (using Bazett correction; QTcB) intervals. The investigator or other qualified physician will interpret each ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant. | Baseline to Day 9 |
| Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings | Laboratory tests for hematology, serum chemistries, coagulation tests, and urinalysis will be performed. | Baseline up to Day 9 |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 7 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug. | Baseline up to Day 9 |
| Safety of TAK-438 | Assessed by physical examination, ECG, and safety tests of blood/urine | 3 months |
| Tolerability of TAK-438 | Assessed by adverse events | 3 months |
| Pharmacokinetic analysis of plasma TAK-438 concentrations | Primary pharmacokinetic parameters (AUC (0-tlqc), AUC (0-inf), Cmax) for TAK-438 and its metabolites M-I, M-II, M-III and M-IV-Sul will be subject to statistical analysis | 3 months |
| Pharmacodynamic measurement for assay of gastric pH, measurement of gastrin, pepsinogen I, pepsinogen II and the pepsinogen I/II ratio in plasma samples | 3 months |
| Percentage of Time the pH is Greater than pH 4 and pH 5 over a 48 Hour Period | Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 48-hour period following the administration of study drug on Day 7. | Over a 48-hour period following the administration of study on Day 7 |
| Percentage of Time the PH is Greater than pH 4 and pH 5 from 8 PM to 8 AM | Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 12-hour period from 8 PM to 8 AM to assess nocturnal pH. | Over a 12-hour period from 8 PM to 8 AM on Days 1, 4 and 7 |
| Total Amount of Gastrin in Plasma | Predose Days 1 through 7 and Days 8 and 9 |
| Total Amount of Pepsinogen I in Plasma | Predose Days 1 through 7 and Days 8 and 9 |
| Total Amount of Pepsinogen II in Plasma | Predose Days 1 through 7 and Days 8 and 9 |
| Pepsinogen I/II Ratio in Plasma | Predose Days 1 through 7 and Days 8 and 9 |
| D004066 | Digestive System Diseases |